Filing Flows › Coherus Oncology (CHRS) › Toripalimab revenue
Coherus Oncology (CHRS) Toripalimab revenue by quarter
Coherus Oncology's Toripalimab revenue was $13.6M in Q2 2026 (second quarter 2026), +15% from Q1 2026. Over the last 6 quarters it ranged from $7.3M (Q1 2025) to $13.6M (Q2 2026).
| Quarter | Toripalimab revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $13.6M | +15% | +37% |
| Q1 2026 | $11.8M | -5% | +61% |
| Q4 2025 | $12.4M | +11% | — |
| Q3 2025 | $11.2M | +12% | — |
| Q2 2025 | $10.0M | +36% | — |
| Q1 2025 | $7.3M | — | — |
Q2 2026 at a glance
Coherus Oncology, Q2 2026: revenue $14.3M (+40% year over year), operating margin -226.0%, net loss $20.6M, operating cash flow −$62.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Coherus Oncology's Toripalimab revenue?
Coherus Oncology's Toripalimab revenue was $13.6M in Q2 2026 (second quarter 2026), +15% from Q1 2026.
How has Coherus Oncology's Toripalimab revenue changed?
Over the last 6 quarters it ranged from $7.3M (Q1 2025) to $13.6M (Q2 2026).